Biotech Awards 2017

and their derivatives represent more than 50% of all the drugs in clinical use in the world. Further, by the beginning of 21st century, 11% of 252 drugs considered essential by the WHO are exclusively of flowering plant origin. The challenge with botanical based products can be generalized into two areas, i.e. standardization of nutrient profiles to consistently deliver a patient with therapeutically effective doses of bioavailable nutrients and the “Fuzzy Science” that is often positioned to consumers as a definitive treatment.” “In addition, the biological action of botanicals and their nutrients is currently not well understood. There is a growing transition amongst consumers towards self-medication and natural health products for the many chronic and incurable health conditions. Along with this trend is a resistance towards prescribed medications, particularly when a natural option has a chance of success. Consumers are also trending towards socially responsible behaviours which include moving towards vegan, non-GMO Company: Arbor Life Labs Website: Brand: and organic dietary consumption. This trend has also extended to the cosmetic world where consumers who care about what they put in or on their body, are increasingly demanding products with transparency demonstrating low or no carcinogens, allergens, reproductive or endocrine disruptors. Finally, more consumers are adequately informed and they are demanding scientific proof of product claims. Providing consumers with non-drug solutions to meet all of these varied needs is both a challenge and an opportunity for which our firm is well positioned to capitalize on this emerging consumer reality.” Looking ahead, Arbor is extending its science into a broad regenerative and anti-ageing platform of multiple cell and tissue types including skin, nervous system, cardiovascular, bone, muscle and connective tissue. This has far reaching opportunities for anti-aging, preventive health and sport, and the firm is excited for the additional chances it will have to build upon its current success. Peter Feldman, CEO